159 related articles for article (PubMed ID: 24486594)
41. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
[TBL] [Abstract][Full Text] [Related]
42. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.
Manceau G; Marisa L; Boige V; Duval A; Gaub MP; Milano G; Selves J; Olschwang S; Jooste V; le Legrain M; Lecorre D; Guenot D; Etienne-Grimaldi MC; Kirzin S; Martin L; Lepage C; Bouvier AM; Laurent-Puig P
Cancer Med; 2015 Mar; 4(3):371-82. PubMed ID: 25641861
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.
Sargent DJ; Resnick MB; Meyers MO; Goldar-Najafi A; Clancy T; Gill S; Siemons GO; Shi Q; Bot BM; Wu TT; Beaudry G; Haince JF; Fradet Y
Ann Surg Oncol; 2011 Nov; 18(12):3261-70. PubMed ID: 21533822
[TBL] [Abstract][Full Text] [Related]
44. Colon cancer prognosis prediction by gene expression profiling.
Barrier A; Lemoine A; Boelle PY; Tse C; Brault D; Chiappini F; Breittschneider J; Lacaine F; Houry S; Huguier M; Van der Laan MJ; Speed T; Debuire B; Flahault A; Dudoit S
Oncogene; 2005 Sep; 24(40):6155-64. PubMed ID: 16091735
[TBL] [Abstract][Full Text] [Related]
45. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
[TBL] [Abstract][Full Text] [Related]
46. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.
Smith JJ; Deane NG; Wu F; Merchant NB; Zhang B; Jiang A; Lu P; Johnson JC; Schmidt C; Bailey CE; Eschrich S; Kis C; Levy S; Washington MK; Heslin MJ; Coffey RJ; Yeatman TJ; Shyr Y; Beauchamp RD
Gastroenterology; 2010 Mar; 138(3):958-68. PubMed ID: 19914252
[TBL] [Abstract][Full Text] [Related]
47. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
[TBL] [Abstract][Full Text] [Related]
48. Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population.
Kjaer-Frifeldt S; Fredslund R; Lindebjerg J; Hansen TF; Spindler KL; Jakobsen A;
Pharmacogenomics; 2012 May; 13(7):763-70. PubMed ID: 22594508
[TBL] [Abstract][Full Text] [Related]
49. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
[TBL] [Abstract][Full Text] [Related]
50. Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer.
Eyking A; Ey B; Rünzi M; Roig AI; Reis H; Schmid KW; Gerken G; Podolsky DK; Cario E
Gastroenterology; 2011 Dec; 141(6):2154-65. PubMed ID: 21920464
[TBL] [Abstract][Full Text] [Related]
51. Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues.
Cimino D; Fuso L; Sfiligoi C; Biglia N; Ponzone R; Maggiorotto F; Russo G; Cicatiello L; Weisz A; Taverna D; Sismondi P; De Bortoli M
Int J Cancer; 2008 Sep; 123(6):1327-38. PubMed ID: 18561318
[TBL] [Abstract][Full Text] [Related]
52. Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer?
Wang J; Kulaylat M; Rockette H; Hassett J; Rajput A; Dunn KB; Dayton M
Ann Surg; 2009 Apr; 249(4):559-63. PubMed ID: 19300237
[TBL] [Abstract][Full Text] [Related]
53. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
54. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.
Popovici V; Budinska E; Tejpar S; Weinrich S; Estrella H; Hodgson G; Van Cutsem E; Xie T; Bosman FT; Roth AD; Delorenzi M
J Clin Oncol; 2012 Apr; 30(12):1288-95. PubMed ID: 22393095
[TBL] [Abstract][Full Text] [Related]
55. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
56. Clinical impact of elastic laminal invasion in colon cancer: elastic laminal invasion-positive stage II colon cancer is a high-risk equivalent to stage III.
Yokota M; Kojima M; Nomura S; Nishizawa Y; Kobayashi A; Ito M; Ochiai A; Saito N
Dis Colon Rectum; 2014 Jul; 57(7):830-8. PubMed ID: 24901683
[TBL] [Abstract][Full Text] [Related]
57. Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.
den Uil SH; Coupé VM; Linnekamp JF; van den Broek E; Goos JA; Delis-van Diemen PM; Belt EJ; van Grieken NC; Scott PM; Vermeulen L; Medema JP; Bril H; Stockmann HB; Cormier RT; Meijer GA; Fijneman RJ
Br J Cancer; 2016 Dec; 115(12):1565-1574. PubMed ID: 27855440
[TBL] [Abstract][Full Text] [Related]
58. [Expression of TROP2 mRNA in left-sided and right-sided colon cancer and its clinical significance].
Xu KY; Gu J
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 May; 12(3):285-9. PubMed ID: 19434540
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle.
Ahmed FE; Ahmed NC; Vos PW; Bonnerup C; Atkins JN; Casey M; Nuovo GJ; Naziri W; Wiley JE; Mota H; Allison RR
Cancer Genomics Proteomics; 2013; 10(3):93-113. PubMed ID: 23741026
[TBL] [Abstract][Full Text] [Related]
60. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
